Literature DB >> 14567560

Elevated levels of anti-Helicobacter pylori antibodies in Henoch-Schönlein purpura.

János Novák1, Zoltán Szekanecz, Judit Sebesi, Alajos Takáts, Pál Demeter, László Bene, Sándor Sipka, Zoltán Csiki.   

Abstract

OBJECTIVE: Henoch-Schonlein purpura (HSP) is a systemic vasculitis characterized by IgA-containing deposits in the skin, joints, gastrointestinal mucosa and glomeruli. HSP is much rarer in adults than in children. Among a number of other pathogenic factors, Helicobacter pylori (Hp) has recently been implicated in the gastrointestinal and extra-gastrointestinal manifestations underlying HSP. We aimed at studying the occurrence of Hp infections in 11 adult HSP patients with appearance in our clinical practice in the last 5 years.
METHODS: Eleven adult HSP and 20 healthy adult patients were recruited for this study. Anti-Hp IgG and IgA antibodies were assessed in sera of HSP patients with active (n = 5) and remittent disease (n = 6) and healthy controls (n = 20) in the context of clinical symptoms, endoscopic evaluation, as well as routine and immunolaboratory observations. Concurrent Hp infection was confirmed by urease test and histology.
RESULTS: Anti-Hp antibodies were present in 10/11 of HSP patients, and 11/20 of healthy controls. However, only 4/11 HSP patients had concurrent Hp infection as confirmed by urease test and/or histology. In the healthy controls the actual Hp infection was detectable in 9/20 cases. Patients in the acute phase had significantly higher levels of anti-Hp IgG compared to healthy controls (86.0 +/- 32.0 versus 25.5 +/- 28.5 U/ml, p < 0.05). In contrast, anti-Hp IgA/IgG ratios were significantly higher in the remitting phase compared to the control group (3.1 +/- 1.8 versus 0.8 +/- 0.5 ratio, p < 0.05). Among other immunolaboratory markers, serum CRP, circulating IgA and serum tumor necrosis factor-alpha levels were significantly increased in acute patients compared to healthy group results (45.3 +/- 22.7 versus 4.8 +/- 3.5 mg/l, p < 0,05); (58.9 +/- 18.2 versus 25.2 +/- 6.4pg/ml, p < 0,05); (5.5 +/- 1.1 versus 2.4 +/- 1.2 g/l; respectively, p < 0.05).
CONCLUSIONS: Hp infection may be associated with the development and progression of HSP. IgG antibodies to Hp may be present mostly in acute HSP, while IgA antibodies may be involved in sustaining gastrointestinal symptoms underlying the chronic phase of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567560     DOI: 10.1080/08916930232000114535

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  10 in total

Review 1.  Current views of the relationship between Helicobacter pylori and Henoch-Schonlein purpura in children.

Authors:  Li-Jing Xiong; Meng Mao
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 2.  Gastrointestinal manifestations of Henoch-Schonlein Purpura.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

Review 3.  Hematologic manifestations of Helicobacter pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

4.  Helicobacter pylori infection: effect on malnutrition and growth failure in dyspeptic children.

Authors:  Ozlem Bekem Soylu; Yesim Ozturk
Journal:  Eur J Pediatr       Date:  2007-07-06       Impact factor: 3.183

5.  The first case of Henoch-Schonlein purpura associated with rosuvastatin: colonic involvement coexisting with small intestine.

Authors:  Korcan Aysun Gonen; Gamze Erfan; Meltem Oznur; Cuneyt Erdogan
Journal:  BMJ Case Rep       Date:  2014-03-19

6.  Gastrointestinal involvement revealing Henoch Schonlein purpura in adults: Report of three cases and review of the literature.

Authors:  Amira Hamzaoui; Wissem Melki; Olfa Harzallah; Leila Njim; Rim Klii; Silvia Mahjoub
Journal:  Int Arch Med       Date:  2011-09-29

7.  Rapid response of Henoch-Schönlein purpura to corticosteroids: correlation between skin and gastric mucosal lesions.

Authors:  Ming-Jen Chen; Wen-Hsiung Chang; Cheng-Hsin Chu; Tsang-En Wang; Shee-Chan Lin; Shou-Chuan Shih
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.487

8.  Rapid improvement of Henoch-Schonlein purpura associated with the treatment of Helicobacter pylori infection.

Authors:  Turgay Ulas; Irfan Tursun; Mehmet Sinan Dal; Mehmet Ali Eren; Hakan Buyukhatipoglu
Journal:  J Res Med Sci       Date:  2012-11       Impact factor: 1.852

9.  Significant association between serum interleukin-6 and Helicobacter pylori antibody levels among H. pylori-positive Japanese adults.

Authors:  Hiroko Nakagawa; Takashi Tamura; Yoko Mitsuda; Yasuyuki Goto; Yoshikazu Kamiya; Takaaki Kondo; Kenji Wakai; Nobuyuki Hamajima
Journal:  Mediators Inflamm       Date:  2013-12-22       Impact factor: 4.711

Review 10.  Helicobacter pylori and extragastric diseases: A review.

Authors:  Antonietta Gerarda Gravina; Rocco Maurizio Zagari; Cristiana De Musis; Lorenzo Romano; Carmelina Loguercio; Marco Romano
Journal:  World J Gastroenterol       Date:  2018-08-07       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.